161 results on '"Waxman, Adam"'
Search Results
2. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
3. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.
4. Radiation Therapy for Plasma Cell Disease of the Brain and Skull: Poor Palliation and Survival After Treatment for Central Nervous System Involvement
5. Human IL-6 fosters long-term engraftment of patient derived disease-driving myeloma cells in immunodeficient mice
6. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma
7. Incidence, Risk Factors, and Clinical Effects of Recurrent Diverticular Hemorrhage: A Large Cohort Study
8. AA amyloidosis associated with Castleman disease: A case report and review of the literature
9. Data from Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
10. Supplementary Tables and Figures from Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
11. Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
12. Progressive multifocal leukoencephalopathy in multiple myeloma
13. Penn State women's hockey stays put in USCHO rankings after dominant sweep of Syracuse
14. Phase 2 Study of Belantamab Mafodotin As Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission
15. Infectious Complications of B-Cell Maturation Antigen (BCMA)-Targeted Therapies for Relapsed/Refractory Multiple Myeloma
16. Coming off a home sweep of Brown, No. 11 Penn State women's hockey looks to take down No. 6 Yale
17. Penn State women's hockey dominates Franklin Pierce in one-sided affair on Saturday
18. Penn State falls to Colgate at home despite solid performance from goaltender Josie Bothun
19. Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis
20. History of Autologous SCT Does Not Appear to Blunt the Serologic Response to COVID-19 Vaccination for Patients with Lymphoid Malignancies
21. Progressive multifocal leukoencephalopathy in multiple myeloma.
22. Racial disparities in incidence and outcome in multiple myeloma: a population-based study
23. Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future
24. Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy
25. Multiple myeloma precursor disease
26. Synthesis and Characterization of Aldol Condensation Products from Unknown Aldehydes and Ketones: An Inquiry-Based Experiment in the Undergraduate Laboratory
27. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
28. Safety and Efficacy of Teclistamab in Patients with Relapsed or Refractory AL Amyloidosis: A Retrospective Case Series
29. A Randomized Controlled Trial of a Financial Navigation Program for Patients with Multiple Myeloma
30. A Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)
31. Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy
32. B‐cell maturation antigen chimeric antigen receptor T‐cell re‐expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor‐based combination therapy
33. High prevalence of polyclonal hypergamma-globulinemia in adult males in Ghana, Africa
34. Progression From Precursor Disease to Multiple Myeloma—Reply
35. Myeloma of the Base of Skull: Palliative Radiotherapy for Cranial Neuropathies
36. A Case Study Progression to Multiple Myeloma
37. 432 - History of Autologous SCT Does Not Appear to Blunt the Serologic Response to COVID-19 Vaccination for Patients with Lymphoid Malignancies
38. Infectious complications following Venetoclax-Proteasome Inhibitor based regimens in relapsed myeloma: a single center retrospective analysis
39. Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma
40. Infectious Complications Following Venetoclax-Proteasome Inhibitor Based Regimens in Relapsed Myeloma: A Single Center Retrospective Analysis
41. Proteasome inhibitor associated cardiovascular adverse events: A real-world claims based study.
42. Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy
43. Cardiovascular Function Phenotypes in Response to Cardiotoxic Breast Cancer Therapy
44. Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM)
45. Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma
46. PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells
47. Proteasome inhibitor associated thrombotic microangiopathy
48. Carfilzomib-associated cardiovascular adverse events: A systematic review and meta-analysis.
49. Proteasome inhibitor associated thrombotic microangiopathy
50. Prospective Study of Cardiac Events during Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.